CompletedNCT00791349

A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone

Medication studyAges 18–50Schizophrenia

The study in practice

Understand this study

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.

Study clarity

Study start dateFebruary 2005

Recruitment status: Completed
Enrollment listed in the registry: 141
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 18 Years to 50 Years
Official registry ID: NCT00791349
Official title: Show the full official title
A Placebo- and Positive-controlled, Randomized Study Evaluating QT and QTc Intervals Following Administration of Immediate-release Paliperidone in Subjects With Schizophrenia or Schizoaffective Disorder

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Immediate release (IR) Paliperidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.